Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Progression-Free Survival Represents Clinical Benefit, But How Much? – ODAC

Executive Summary

While the Oncologic Drugs Advisory Committee generally endorses the idea that progression-free survival can support full approval of first-line therapies in metastatic breast cancer, the panel left FDA with the challenge of qualifying how PFS represents clinical benefit and determining the measure's meaningfulness for regulatory purposes

You may also be interested in...



Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval

Genentech has been clear that it intends to appeal FDA's determination that the breast cancer indication for Avastin should be revoked, but the agency may not let the appeal go forward.

Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval

Genentech has been clear that it intends to appeal FDA's determination that the breast cancer indication for Avastin should be revoked, but the agency may not let the appeal go forward.

Provenge Poised For Broad Insurance Coverage, Despite Grumbles On Price

After a strong endorsement in the National Comprehensive Cancer Network guidelines, Dendreon's first-of-its-kind prostate cancer vaccine Provenge appears well positioned for broad insurance coverage and take-up with physicians

Related Content

UsernamePublicRestriction

Register

PS049132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel